Cas9 Stable Cell Line - HGC-27

The HGC-27 cell line, derived from metastatic lymph nodes of a 60-year-old female gastric cancer patient, represents an epithelial-morphological model of undifferentiated gastric cancer. These cells exhibit an adherent growth pattern and possess valuable properties for oncology research, including tumorigenicity in immunodeficient mice and expression of specific gastric cancer biomarkers. The Cas9-stable HGC-27 cell line was constructed by transducing the Streptococcus pyogenes Cas9 nuclease gene. This cell line exhibited a stable proliferation rate comparable to parental HGC-27 cells and maintained robust Cas9 activity after multiple passages without significant silencing.

This Cas9 Stable Cell Line - HGC-27 has applications in multiple fields, including functional genomics and therapeutic drug development. Researchers used this cell line for high-throughput CRISPR screening to identify novel therapeutic targets in gastric cancer pathways, particularly those involved in metastasis and drug resistance mechanisms. Stable Cas9 expression eliminates transfection variability, enabling reproducible construction of homologous cell models via single-guide RNA delivery, allowing for precise gene knockout, knock-in, or base editing. This facilitates the study of gene function in tumor progression, microenvironment interactions, and metabolic reprogramming. The cell line supports the drug discovery process by rapidly validating candidate targets and assessing synthetic lethal interactions using a combined CRISPR/sgRNA approach. Furthermore, this model can serve as a platform for constructing personalized cancer models, accelerating the preclinical evaluation of targeted therapies by introducing patient-specific mutations.